A Phase 2 Trial Of PF-04856884 (CVX-060), A Selective Angiopoietin-2 (Ang-2) Binding CovX-body, In Patients With Recurrent Glioblastoma
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 19 Mar 2015
At a glance
- Drugs PF 4856884 (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- Sponsors Pfizer
- 22 Dec 2010 Trial location (USA) identified as reported by ClinicalTrials.gov.
- 22 Dec 2010 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 27 Oct 2010 New trial record